Patent · US Active

Factor XI antibodies and methods of use

US12012464B2 · kind B2 · utility

0Cited by

70References

18Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Maximilian Aigner · Redmond, US
Alexander Koch · Arlington, US
Markus Waldhuber · Munich, DE

Key dates

Filing date	Oct 6, 2021
Grant date	Jun 18, 2024
Priority date	—
Expiry date	Apr 9, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.